Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S.

Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. No abstract available.

2.

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P.

Hematol Oncol. 2017 Dec;35(4):671-678. doi: 10.1002/hon.2370. Epub 2016 Nov 22.

PMID:
27878835
3.

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G.

Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5.

4.

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.

Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V.

Leuk Lymphoma. 2016 Feb;57(2):328-334. doi: 10.3109/10428194.2015.1063139. Epub 2015 Sep 28.

PMID:
26140301
5.

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.

Fornecker LM, Aurran-Schleinitz T, Michallet AS, Cazin B, Guieze R, Dilhuydy MS, Zini JM, Tomowiak C, Lepretre S, Cymbalista F, Brion A, Feugier P, Delmer A, Leblond V, Ysebaert L.

Am J Hematol. 2015 Jun;90(6):511-4. doi: 10.1002/ajh.23999. Epub 2015 Apr 1.

6.

Bendamustine is effective in T-cell prolymphocytic leukaemia.

Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S, Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L.

Br J Haematol. 2015 Mar;168(6):916-9. doi: 10.1111/bjh.13175. Epub 2014 Oct 15. No abstract available.

PMID:
25316212
7.

First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.

Michallet AS, Cazin B, Bouvet E, Oberic L, Schlaifer D, Mosser L, Salles G, Coiffier B, Laurent G, Ysebaert L.

J Geriatr Oncol. 2013 Apr;4(2):141-7. doi: 10.1016/j.jgo.2013.01.002. Epub 2013 Feb 26.

PMID:
24071539
8.

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study.

Van Den Neste E, Cazin B, Janssens A, González-Barca E, Terol MJ, Levy V, Pérez de Oteyza J, Zachee P, Saunders A, de Frias M, Campàs C.

Cancer Chemother Pharmacol. 2013 Mar;71(3):581-91. doi: 10.1007/s00280-012-2033-5. Epub 2012 Dec 11.

9.

[Chronic lymphocytic leukaemia presenting with specific cutaneous infiltrates in the absence of lymphocytosis: Two cases].

Vonarx M, Carpentier O, Cazin B, Bouchindhomme B, Delaporte E.

Ann Dermatol Venereol. 2012 Oct;139(10):641-6. doi: 10.1016/j.annder.2012.06.040. Epub 2012 Sep 1. French.

PMID:
23122378
10.

Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.

Bouvet E, Borel C, Obéric L, Compaci G, Cazin B, Michallet AS, Laurent G, Ysebaert L.

Haematologica. 2013 Jan;98(1):65-70. doi: 10.3324/haematol.2012.070755. Epub 2012 Oct 12.

11.

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P.

Blood. 2012 May 31;119(22):5104-10. doi: 10.1182/blood-2011-07-365437. Epub 2012 Feb 14.

PMID:
22337714
12.

Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia.

Michallet AS, Rossignol J, Cazin B, Ysebaert L.

Leuk Lymphoma. 2011 Jul;52(7):1401-3. doi: 10.3109/10428194.2011.591005. Retraction in: Leuk Lymphoma. 2016 Sep;57(9):2240.

PMID:
21699387
13.

Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia.

Rossignol J, Michallet AS, Oberic L, Picard M, Garon A, Willekens C, Dulery R, Leleu X, Cazin B, Ysebaert L.

Leukemia. 2011 Mar;25(3):473-8. doi: 10.1038/leu.2010.278. Epub 2010 Dec 3.

PMID:
21127498
14.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group.

Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.

PMID:
20888994
15.

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.

Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE.

Br J Haematol. 2010 Jun;149(6):907-10. doi: 10.1111/j.1365-2141.2010.08134.x. Epub 2010 Mar 1. No abstract available.

PMID:
20201944
16.

IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.

Maloum K, Settegrana C, Chapiro E, Cazin B, Leprêtre S, Delmer A, Leporrier M, Dreyfus B, Tournilhac O, Mahe B, Nguyen-Khac F, Lesty C, Davi F, Merle-Béral H.

Ann Hematol. 2009 Dec;88(12):1215-21. doi: 10.1007/s00277-009-0742-6. Epub 2009 Apr 2.

PMID:
19340428
17.

High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.

Cazin B, Divine M, Leprêtre S, Travade P, Tournilhac O, Delmer A, Jaubert J, Feugier P, Dreyfus B, Mahé B, Grosbois B, Maloisel F, Eghbali H, Dumontet C, Bénichou J, Guibon O, Leleu X, Leporrier M, Maloum K.

Br J Haematol. 2008 Oct;143(1):54-9. doi: 10.1111/j.1365-2141.2008.07309.x. Epub 2008 Aug 15.

PMID:
18710390
18.

Autologous activated macrophages (MAK) coated ex vivo with humanized anti-CD20 monoclonal antibodies can eradicate minimal residual disease in chronic lymphocytic leukaemia in clinical response.

Sutton L, Chaoui D, Cazin B, Azar N, Chokri M, Romet-Lemonne JL, Maloum K.

Br J Haematol. 2008 Sep;142(6):996-8. doi: 10.1111/j.1365-2141.2008.07272.x. Epub 2008 Jul 28. No abstract available.

PMID:
18665839
19.

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.

de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Béliard R, Vieillard V, Cazin B, Bourel D, Prost JF, Teillaud JL, Merle-Béral H.

Br J Haematol. 2008 Mar;140(6):635-43. doi: 10.1111/j.1365-2141.2007.06974.x.

PMID:
18302712
20.

A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia.

Maloum K, Charlotte F, Divine M, Cazin B, Lesty C, Merle-Béral H; French Cooperative Group on CLL.

Haematologica. 2006 Jun;91(6):860-1.

21.

Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.

Tournilhac O, Cazin B, Leprètre S, Diviné M, Maloum K, Delmer A, Grosbois B, Feugier P, Maloisel F, Villard F, Villemagne B, Bastit D, Belhadj K, Azar N, Michallet M, Manhès G, Travade P.

Blood. 2004 Jan 1;103(1):363-5. Epub 2003 Sep 11.

PMID:
12969985
22.

Transplantation in Waldenstrom's macroglobulinemia--the French experience.

Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N, Cazin B, Divine M, Dreyfus B, Cahn JY, Pignon B, Desablens B, Perrier JF, Bay JO, Travade P.

Semin Oncol. 2003 Apr;30(2):291-6.

PMID:
12720155
23.

Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients.

Stalnikiewicz L, Carrotte-Lefebvre I, Detourmignies L, Rose C, Cazin B, Leblond V, Morel P.

Semin Oncol. 2003 Apr;30(2):216-9.

PMID:
12720139
24.

Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission.

Delannoy A, Cazin B, Thomas X, Bouabdallah R, Boiron JM, Huguet F, Straetmans N, Zérazhi H, Vernant JP, Dombret H, Bilhou-Nabera C, Charrin C, Boucheix C, Sebban C, Lhéritier V, Fière D; LALA Group, France and Belgium.

Leuk Lymphoma. 2002 Jan;43(1):75-81.

PMID:
11908739
25.

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P.

J Clin Oncol. 2002 Jan 1;20(1):205-13.

PMID:
11773171
26.

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.

Leblond V, Lévy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, Remenieras L, Porcher R, Gardembas M, Marit G, Deconinck E, Desablens B, Guilhot F, Philippe G, Stamatoullas A, Guibon O; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia.

Blood. 2001 Nov 1;98(9):2640-4.

PMID:
11675332
27.

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.

Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C; French Cooperative Group on Chronic Lymphocytic Leukemia.

Blood. 2001 Oct 15;98(8):2319-25.

PMID:
11588025
28.

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D.

Blood. 2001 Sep 15;98(6):1721-6.

PMID:
11535503
29.

Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.

Lévy V, Porcher R, Leblond V, Fermand JP, Cazin B, Maloisel F, Harousseau JL, Remenieras L, Guibon O, Chevret S; French Cooperative Group on CLL and Macroglobulinemia.

Leukemia. 2001 Sep;15(9):1466-70.

30.

Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.

Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S; French Cooperative CLL Group.

J Clin Epidemiol. 2001 Jul;54(7):747-54.

PMID:
11438417
31.

Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL).

Magnac C, Sutton L, Cazin B, Laurent C, Binet JL, Merle-Béral H, Dighiero G, Maloum K.

Hematol Cell Ther. 1999 Feb;41(1):13-8.

PMID:
10193641
32.

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Travade P.

N Engl J Med. 1998 May 21;338(21):1506-14.

33.

Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic Leukemia.

Delannoy A, Sebban C, Cony-Makhoul P, Cazin B, Cordonnier C, Bouabdallah R, Cahn JY, Dreyfus F, Sadoun A, Vernant JP, Gay C, Broustet A, Michaux JL, Fière D.

Leukemia. 1997 Sep;11(9):1429-34.

34.

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL).

Preudhomme C, Henic N, Cazin B, Lai JL, Bertheas MF, Vanrumbeke M, Lemoine F, Jouet JP, Deconninck E, Nelken B, Cosson A, Fenaux P.

Leukemia. 1997 Feb;11(2):294-8.

35.

Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations.

Madani A, Choukroun V, Soulier J, Cacheux V, Claisse JF, Valensi F, Daliphard S, Cazin B, Levy V, Leblond V, Daniel MT, Sigaux F, Stern MH.

Blood. 1996 Mar 1;87(5):1923-7.

PMID:
8634440
36.

Successful autologous bone marrow transplantation in second remission of malignant histiocytosis.

Cazin B, Gorin NC, Jouet JP, Laporte JP, Fenaux P, Walter MP, Najman A, Gosselin B, Bauters F.

Bone Marrow Transplant. 1990 Jun;5(6):431-3.

PMID:
1695116
37.

Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations.

Cazin B, Gorin NC, Laporte JP, Gallet B, Douay L, Lopez M, Najman A, Duhamel G.

Cancer. 1986 May 15;57(10):2061-9.

PMID:
3513941
38.

[Apropos of febrile polyadenopathy].

Cazin B, Leverger G, Schaison G.

Ann Pediatr (Paris). 1985 Dec;32(10):893-4. French. No abstract available.

PMID:
4091445
39.

[Bullous form of malignant histiocytosis].

Laroche L, Leverger G, Cazin B, Daniel MT, Flandrin G, Schaison G, Civatte J.

Ann Dermatol Venereol. 1985;112(9):729-30. French. No abstract available.

PMID:
3841470
40.

[Paradoxical embolism associated with an interatrial communication].

Bonnichon P, Meyniard O, Boissonnas A, Cazin B, D'Enfert J, Chapuis Y.

Presse Med. 1984 Mar 17;13(11):684. French. No abstract available.

PMID:
6231573

Supplemental Content

Support Center